GlucoTrack, Inc. , a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally.
Glucotrack stock last closed at $5.65, down 1.22% from the previous day, and has decreased 99.72% in one year. It has underperformed other stocks in the Medical Instruments & Supplies industry by 0.39 percentage points. Glucotrack stock is currently +9.07% from its 52-week low of $5.18, and -99.85% from its 52-week high of $3,756.00.
There are currently 477,380 GCTK shares outstanding. The market value of GCTK is $2.70M. In the last 24 hours, 34,000 GCTK shares were traded.
You need an online brokerage account in order to access the NASDAQ market and buy GCTK stock.
Based on our research, eToro is the best place to buy stocks. Here's why:
Get $10 towards your purchase of shares by opening an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've picked your brokerage, the next step is to fill out some personal details so you can invest in GCTK today.
Now that you've opened your account on apps for stocks, you can securely and quickly fund your account:
Watch the walkthrough below if you need help transferring money into your new brokerage account.
Once you have figured out the best place to buy Glucotrack stock, it's crucial to analyze their stock prior to buying, so you can understand the risk and opportunity.
WallStreetZen was built to help average investors perform better fundamental analysis quickly.
You can see all of the due diligence checks on GCTK's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge GCTK's fair value.
Using relative valuations metrics:
You can do more valuation research on GCTK's stock here.
Last year, GCTK revenue was $0.00. Over the last 5 year, GCTK's revenue has gone up by -100% per year. This was slower than the Medical Instruments & Supplies industry average of 10.47%.
You can analyze GCTK's earnings and revenue performance here.
In the last year, insiders at GCTK have bought more shares than they have sold.
John Ballantyne, Director of GCTK, was the latest GCTK insider to buy. They bought $4,093,116.00 worth of GCTK stock on Nov 14, 2024.
Learn more about who owns GCTK shares here.
No, Glucotrack doesn't provide an income stream by paying out dividends.
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
You have two primary order types:
Press the Open Trade button and your broker will execute your order.
If you need additional assistance investing in stocks on eToro, click the helpful video below:
Now that you own some shares in GCTK, you'll want to keep up with your new stock purchase.
Put GCTK on a watchlist to track your GCTK stock.
To reiterate, here are the 6 steps for buying Glucotrack stock:
If you need a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you want to monitor your investment in Glucotrack, create a watchlist today.